JP2012092119A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2012092119A5 JP2012092119A5 JP2011266612A JP2011266612A JP2012092119A5 JP 2012092119 A5 JP2012092119 A5 JP 2012092119A5 JP 2011266612 A JP2011266612 A JP 2011266612A JP 2011266612 A JP2011266612 A JP 2011266612A JP 2012092119 A5 JP2012092119 A5 JP 2012092119A5
- Authority
- JP
- Japan
- Prior art keywords
- composition
- composition according
- poly
- ethylene glycol
- derivatized
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000203 mixture Substances 0.000 claims 41
- 150000002632 lipids Chemical class 0.000 claims 13
- 229920001223 polyethylene glycol Polymers 0.000 claims 11
- 229920001477 hydrophilic polymer Polymers 0.000 claims 10
- 239000002502 liposome Substances 0.000 claims 9
- 230000008685 targeting Effects 0.000 claims 9
- 239000000126 substance Substances 0.000 claims 7
- 230000001225 therapeutic effect Effects 0.000 claims 6
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 claims 5
- -1 sulfate ester Chemical class 0.000 claims 5
- 230000000118 anti-neoplastic effect Effects 0.000 claims 4
- 239000003814 drug Substances 0.000 claims 4
- 229920005862 polyol Polymers 0.000 claims 4
- 150000003077 polyols Chemical class 0.000 claims 4
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims 3
- 108010009202 Growth Factor Receptors Proteins 0.000 claims 3
- 102000009465 Growth Factor Receptors Human genes 0.000 claims 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 claims 3
- 229940123237 Taxane Drugs 0.000 claims 3
- 239000000427 antigen Substances 0.000 claims 3
- 102000036639 antigens Human genes 0.000 claims 3
- 108091007433 antigens Proteins 0.000 claims 3
- 229940034982 antineoplastic agent Drugs 0.000 claims 3
- 229940079593 drug Drugs 0.000 claims 3
- 239000012528 membrane Substances 0.000 claims 3
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 claims 3
- 102000004169 proteins and genes Human genes 0.000 claims 3
- 108090000623 proteins and genes Proteins 0.000 claims 3
- 108091008598 receptor tyrosine kinases Proteins 0.000 claims 3
- 102000027426 receptor tyrosine kinases Human genes 0.000 claims 3
- DKPFODGZWDEEBT-QFIAKTPHSA-N taxane Chemical class C([C@]1(C)CCC[C@@H](C)[C@H]1C1)C[C@H]2[C@H](C)CC[C@@H]1C2(C)C DKPFODGZWDEEBT-QFIAKTPHSA-N 0.000 claims 3
- KLWPJMFMVPTNCC-UHFFFAOYSA-N Camptothecin Natural products CCC1(O)C(=O)OCC2=C1C=C3C4Nc5ccccc5C=C4CN3C2=O KLWPJMFMVPTNCC-UHFFFAOYSA-N 0.000 claims 2
- 108010067225 Cell Adhesion Molecules Proteins 0.000 claims 2
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 claims 2
- SRBFZHDQGSBBOR-IOVATXLUSA-N D-xylopyranose Chemical compound O[C@@H]1COC(O)[C@H](O)[C@H]1O SRBFZHDQGSBBOR-IOVATXLUSA-N 0.000 claims 2
- 229940123780 DNA topoisomerase I inhibitor Drugs 0.000 claims 2
- 241000124008 Mammalia Species 0.000 claims 2
- 239000000365 Topoisomerase I Inhibitor Substances 0.000 claims 2
- 239000002870 angiogenesis inducing agent Substances 0.000 claims 2
- 125000000129 anionic group Chemical group 0.000 claims 2
- PYMYPHUHKUWMLA-UHFFFAOYSA-N arabinose Natural products OCC(O)C(O)C(O)C=O PYMYPHUHKUWMLA-UHFFFAOYSA-N 0.000 claims 2
- SRBFZHDQGSBBOR-UHFFFAOYSA-N beta-D-Pyranose-Lyxose Natural products OC1COC(O)C(O)C1O SRBFZHDQGSBBOR-UHFFFAOYSA-N 0.000 claims 2
- 229940127093 camptothecin Drugs 0.000 claims 2
- VSJKWCGYPAHWDS-FQEVSTJZSA-N camptothecin Chemical compound C1=CC=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 VSJKWCGYPAHWDS-FQEVSTJZSA-N 0.000 claims 2
- 125000002091 cationic group Chemical group 0.000 claims 2
- 102000008395 cell adhesion mediator activity proteins Human genes 0.000 claims 2
- 150000002016 disaccharides Chemical class 0.000 claims 2
- VSJKWCGYPAHWDS-UHFFFAOYSA-N dl-camptothecin Natural products C1=CC=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)C5(O)CC)C4=NC2=C1 VSJKWCGYPAHWDS-UHFFFAOYSA-N 0.000 claims 2
- 239000003534 dna topoisomerase inhibitor Substances 0.000 claims 2
- 125000000524 functional group Chemical group 0.000 claims 2
- 150000002772 monosaccharides Chemical class 0.000 claims 2
- 235000002949 phytic acid Nutrition 0.000 claims 2
- 108090000765 processed proteins & peptides Proteins 0.000 claims 2
- 102000005962 receptors Human genes 0.000 claims 2
- 108020003175 receptors Proteins 0.000 claims 2
- 150000003384 small molecules Chemical class 0.000 claims 2
- 150000003445 sucroses Polymers 0.000 claims 2
- 229940044693 topoisomerase inhibitor Drugs 0.000 claims 2
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 claims 1
- BGPJLYIFDLICMR-UHFFFAOYSA-N 1,4,2,3-dioxadithiolan-5-one Chemical group O=C1OSSO1 BGPJLYIFDLICMR-UHFFFAOYSA-N 0.000 claims 1
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 claims 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 claims 1
- YDNKGFDKKRUKPY-JHOUSYSJSA-N C16 ceramide Natural products CCCCCCCCCCCCCCCC(=O)N[C@@H](CO)[C@H](O)C=CCCCCCCCCCCCCC YDNKGFDKKRUKPY-JHOUSYSJSA-N 0.000 claims 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 claims 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims 1
- HEBKCHPVOIAQTA-QWWZWVQMSA-N D-arabinitol Chemical compound OC[C@@H](O)C(O)[C@H](O)CO HEBKCHPVOIAQTA-QWWZWVQMSA-N 0.000 claims 1
- HMFHBZSHGGEWLO-SOOFDHNKSA-N D-ribofuranose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H]1O HMFHBZSHGGEWLO-SOOFDHNKSA-N 0.000 claims 1
- 101150029707 ERBB2 gene Proteins 0.000 claims 1
- 239000004386 Erythritol Substances 0.000 claims 1
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 claims 1
- VGGSQFUCUMXWEO-UHFFFAOYSA-N Ethene Chemical compound C=C VGGSQFUCUMXWEO-UHFFFAOYSA-N 0.000 claims 1
- 239000005977 Ethylene Substances 0.000 claims 1
- 102100024785 Fibroblast growth factor 2 Human genes 0.000 claims 1
- 108090000379 Fibroblast growth factor 2 Proteins 0.000 claims 1
- 229930091371 Fructose Natural products 0.000 claims 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 claims 1
- 239000005715 Fructose Substances 0.000 claims 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims 1
- SQUHHTBVTRBESD-UHFFFAOYSA-N Hexa-Ac-myo-Inositol Natural products CC(=O)OC1C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C1OC(C)=O SQUHHTBVTRBESD-UHFFFAOYSA-N 0.000 claims 1
- IMQLKJBTEOYOSI-GPIVLXJGSA-N Inositol-hexakisphosphate Chemical group OP(O)(=O)O[C@H]1[C@H](OP(O)(O)=O)[C@@H](OP(O)(O)=O)[C@H](OP(O)(O)=O)[C@H](OP(O)(O)=O)[C@@H]1OP(O)(O)=O IMQLKJBTEOYOSI-GPIVLXJGSA-N 0.000 claims 1
- LKDRXBCSQODPBY-AMVSKUEXSA-N L-(-)-Sorbose Chemical compound OCC1(O)OC[C@H](O)[C@@H](O)[C@@H]1O LKDRXBCSQODPBY-AMVSKUEXSA-N 0.000 claims 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 claims 1
- 229930195725 Mannitol Natural products 0.000 claims 1
- CRJGESKKUOMBCT-VQTJNVASSA-N N-acetylsphinganine Chemical compound CCCCCCCCCCCCCCC[C@@H](O)[C@H](CO)NC(C)=O CRJGESKKUOMBCT-VQTJNVASSA-N 0.000 claims 1
- 229910019142 PO4 Inorganic materials 0.000 claims 1
- ABLZXFCXXLZCGV-UHFFFAOYSA-N Phosphorous acid Chemical group OP(O)=O ABLZXFCXXLZCGV-UHFFFAOYSA-N 0.000 claims 1
- IMQLKJBTEOYOSI-UHFFFAOYSA-N Phytic acid Natural products OP(O)(=O)OC1C(OP(O)(O)=O)C(OP(O)(O)=O)C(OP(O)(O)=O)C(OP(O)(O)=O)C1OP(O)(O)=O IMQLKJBTEOYOSI-UHFFFAOYSA-N 0.000 claims 1
- 101710100969 Receptor tyrosine-protein kinase erbB-3 Proteins 0.000 claims 1
- 101710100963 Receptor tyrosine-protein kinase erbB-4 Proteins 0.000 claims 1
- JVWLUVNSQYXYBE-UHFFFAOYSA-N Ribitol Natural products OCC(C)C(O)C(O)CO JVWLUVNSQYXYBE-UHFFFAOYSA-N 0.000 claims 1
- PYMYPHUHKUWMLA-LMVFSUKVSA-N Ribose Natural products OC[C@@H](O)[C@@H](O)[C@@H](O)C=O PYMYPHUHKUWMLA-LMVFSUKVSA-N 0.000 claims 1
- 108010003723 Single-Domain Antibodies Proteins 0.000 claims 1
- 229930182558 Sterol Natural products 0.000 claims 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims 1
- 229930006000 Sucrose Natural products 0.000 claims 1
- 102000007238 Transferrin Receptors Human genes 0.000 claims 1
- 108010033576 Transferrin Receptors Proteins 0.000 claims 1
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 claims 1
- 108091008605 VEGF receptors Proteins 0.000 claims 1
- 102000009484 Vascular Endothelial Growth Factor Receptors Human genes 0.000 claims 1
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 claims 1
- 239000002253 acid Substances 0.000 claims 1
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 claims 1
- HMFHBZSHGGEWLO-UHFFFAOYSA-N alpha-D-Furanose-Ribose Natural products OCC1OC(O)C(O)C1O HMFHBZSHGGEWLO-UHFFFAOYSA-N 0.000 claims 1
- WQZGKKKJIJFFOK-PHYPRBDBSA-N alpha-D-galactose Chemical compound OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-PHYPRBDBSA-N 0.000 claims 1
- PYMYPHUHKUWMLA-WDCZJNDASA-N arabinose Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)C=O PYMYPHUHKUWMLA-WDCZJNDASA-N 0.000 claims 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 claims 1
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 claims 1
- 229940106189 ceramide Drugs 0.000 claims 1
- ZVEQCJWYRWKARO-UHFFFAOYSA-N ceramide Natural products CCCCCCCCCCCCCCC(O)C(=O)NC(CO)C(O)C=CCCC=C(C)CCCCCCCCC ZVEQCJWYRWKARO-UHFFFAOYSA-N 0.000 claims 1
- 150000001982 diacylglycerols Chemical class 0.000 claims 1
- 150000001985 dialkylglycerols Chemical class 0.000 claims 1
- 235000014113 dietary fatty acids Nutrition 0.000 claims 1
- 108700015053 epidermal growth factor receptor activity proteins Proteins 0.000 claims 1
- 102000052116 epidermal growth factor receptor activity proteins Human genes 0.000 claims 1
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 claims 1
- 235000019414 erythritol Nutrition 0.000 claims 1
- 229940009714 erythritol Drugs 0.000 claims 1
- 229930195729 fatty acid Natural products 0.000 claims 1
- 239000000194 fatty acid Substances 0.000 claims 1
- 150000004665 fatty acids Chemical class 0.000 claims 1
- 150000002191 fatty alcohols Chemical class 0.000 claims 1
- 239000012634 fragment Substances 0.000 claims 1
- 229930182830 galactose Natural products 0.000 claims 1
- 239000008103 glucose Substances 0.000 claims 1
- 150000004676 glycans Chemical class 0.000 claims 1
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 claims 1
- CDAISMWEOUEBRE-GPIVLXJGSA-N inositol Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](O)[C@@H]1O CDAISMWEOUEBRE-GPIVLXJGSA-N 0.000 claims 1
- 229960000367 inositol Drugs 0.000 claims 1
- 102000006495 integrins Human genes 0.000 claims 1
- 108010044426 integrins Proteins 0.000 claims 1
- 229960004768 irinotecan Drugs 0.000 claims 1
- UWKQSNNFCGGAFS-XIFFEERXSA-N irinotecan Chemical compound C1=C2C(CC)=C3CN(C(C4=C([C@@](C(=O)OC4)(O)CC)C=4)=O)C=4C3=NC2=CC=C1OC(=O)N(CC1)CCC1N1CCCCC1 UWKQSNNFCGGAFS-XIFFEERXSA-N 0.000 claims 1
- 239000000832 lactitol Substances 0.000 claims 1
- 235000010448 lactitol Nutrition 0.000 claims 1
- VQHSOMBJVWLPSR-JVCRWLNRSA-N lactitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-JVCRWLNRSA-N 0.000 claims 1
- 229960003451 lactitol Drugs 0.000 claims 1
- 239000008101 lactose Substances 0.000 claims 1
- 230000003211 malignant effect Effects 0.000 claims 1
- VQHSOMBJVWLPSR-WUJBLJFYSA-N maltitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-WUJBLJFYSA-N 0.000 claims 1
- 239000000845 maltitol Substances 0.000 claims 1
- 235000010449 maltitol Nutrition 0.000 claims 1
- 229940035436 maltitol Drugs 0.000 claims 1
- 239000000594 mannitol Substances 0.000 claims 1
- 235000010355 mannitol Nutrition 0.000 claims 1
- 229960001855 mannitol Drugs 0.000 claims 1
- YOHYSYJDKVYCJI-UHFFFAOYSA-N n-[3-[[6-[3-(trifluoromethyl)anilino]pyrimidin-4-yl]amino]phenyl]cyclopropanecarboxamide Chemical group FC(F)(F)C1=CC=CC(NC=2N=CN=C(NC=3C=C(NC(=O)C4CC4)C=CC=3)C=2)=C1 YOHYSYJDKVYCJI-UHFFFAOYSA-N 0.000 claims 1
- VVGIYYKRAMHVLU-UHFFFAOYSA-N newbouldiamide Natural products CCCCCCCCCCCCCCCCCCCC(O)C(O)C(O)C(CO)NC(=O)CCCCCCCCCCCCCCCCC VVGIYYKRAMHVLU-UHFFFAOYSA-N 0.000 claims 1
- 238000007911 parenteral administration Methods 0.000 claims 1
- WXZMFSXDPGVJKK-UHFFFAOYSA-N pentaerythritol Chemical compound OCC(CO)(CO)CO WXZMFSXDPGVJKK-UHFFFAOYSA-N 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 239000010452 phosphate Substances 0.000 claims 1
- 150000003904 phospholipids Chemical class 0.000 claims 1
- 229940068041 phytic acid Drugs 0.000 claims 1
- 102000040430 polynucleotide Human genes 0.000 claims 1
- 108091033319 polynucleotide Proteins 0.000 claims 1
- 239000002157 polynucleotide Substances 0.000 claims 1
- 229920001184 polypeptide Polymers 0.000 claims 1
- 229920001282 polysaccharide Polymers 0.000 claims 1
- 239000005017 polysaccharide Substances 0.000 claims 1
- 230000003389 potentiating effect Effects 0.000 claims 1
- 102000004196 processed proteins & peptides Human genes 0.000 claims 1
- HEBKCHPVOIAQTA-ZXFHETKHSA-N ribitol Chemical compound OC[C@H](O)[C@H](O)[C@H](O)CO HEBKCHPVOIAQTA-ZXFHETKHSA-N 0.000 claims 1
- 150000003839 salts Chemical class 0.000 claims 1
- CDAISMWEOUEBRE-UHFFFAOYSA-N scyllo-inosotol Natural products OC1C(O)C(O)C(O)C(O)C1O CDAISMWEOUEBRE-UHFFFAOYSA-N 0.000 claims 1
- 239000000600 sorbitol Substances 0.000 claims 1
- 229960002920 sorbitol Drugs 0.000 claims 1
- 235000010356 sorbitol Nutrition 0.000 claims 1
- 150000003432 sterols Chemical class 0.000 claims 1
- 235000003702 sterols Nutrition 0.000 claims 1
- 239000005720 sucrose Substances 0.000 claims 1
- 125000000185 sucrose group Polymers 0.000 claims 1
- WEPNHBQBLCNOBB-FZJVNAOYSA-N sucrose octasulfate Chemical group OS(=O)(=O)O[C@@H]1[C@H](OS(O)(=O)=O)[C@H](COS(=O)(=O)O)O[C@]1(COS(O)(=O)=O)O[C@@H]1[C@H](OS(O)(=O)=O)[C@@H](OS(O)(=O)=O)[C@@H](OS(O)(=O)=O)[C@@H](COS(O)(=O)=O)O1 WEPNHBQBLCNOBB-FZJVNAOYSA-N 0.000 claims 1
- QAOWNCQODCNURD-UHFFFAOYSA-L sulfate group Chemical group S(=O)(=O)([O-])[O-] QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 claims 1
- 125000001273 sulfonato group Chemical group [O-]S(*)(=O)=O 0.000 claims 1
- 229940124597 therapeutic agent Drugs 0.000 claims 1
- 102000035029 vitamin receptors Human genes 0.000 claims 1
- 108091005463 vitamin receptors Proteins 0.000 claims 1
- 239000000811 xylitol Substances 0.000 claims 1
- 235000010447 xylitol Nutrition 0.000 claims 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 claims 1
- 229960002675 xylitol Drugs 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US56792104P | 2004-05-03 | 2004-05-03 | |
| US60/567,921 | 2004-05-03 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2007511506A Division JP4971142B2 (ja) | 2004-05-03 | 2005-05-02 | 薬物送達に有用なリポソーム |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013241469A Division JP5665950B2 (ja) | 2004-05-03 | 2013-11-22 | 薬物送達に有用なリポソーム |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2012092119A JP2012092119A (ja) | 2012-05-17 |
| JP2012092119A5 true JP2012092119A5 (enExample) | 2013-02-28 |
| JP5502842B2 JP5502842B2 (ja) | 2014-05-28 |
Family
ID=35320018
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2007511506A Expired - Lifetime JP4971142B2 (ja) | 2004-05-03 | 2005-05-02 | 薬物送達に有用なリポソーム |
| JP2011266612A Expired - Lifetime JP5502842B2 (ja) | 2004-05-03 | 2011-12-06 | 薬物送達に有用なリポソーム |
| JP2013241469A Expired - Lifetime JP5665950B2 (ja) | 2004-05-03 | 2013-11-22 | 薬物送達に有用なリポソーム |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2007511506A Expired - Lifetime JP4971142B2 (ja) | 2004-05-03 | 2005-05-02 | 薬物送達に有用なリポソーム |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013241469A Expired - Lifetime JP5665950B2 (ja) | 2004-05-03 | 2013-11-22 | 薬物送達に有用なリポソーム |
Country Status (23)
| Country | Link |
|---|---|
| US (22) | US8147867B2 (enExample) |
| EP (3) | EP4218730B1 (enExample) |
| JP (3) | JP4971142B2 (enExample) |
| KR (4) | KR101376895B1 (enExample) |
| CN (3) | CN1980637B (enExample) |
| AU (1) | AU2005240131C1 (enExample) |
| CA (4) | CA2928387A1 (enExample) |
| CY (1) | CY2025003I1 (enExample) |
| DK (1) | DK1746976T3 (enExample) |
| ES (2) | ES2967961T3 (enExample) |
| FI (2) | FI3173073T3 (enExample) |
| FR (1) | FR17C1027I2 (enExample) |
| HU (2) | HUE068934T2 (enExample) |
| LT (2) | LT3173073T (enExample) |
| LU (1) | LUC00026I2 (enExample) |
| NL (1) | NL300885I2 (enExample) |
| NO (2) | NO345218B1 (enExample) |
| PL (1) | PL1746976T3 (enExample) |
| PT (1) | PT1746976T (enExample) |
| RU (3) | RU2424792C2 (enExample) |
| TW (1) | TWI359029B (enExample) |
| UA (1) | UA86063C2 (enExample) |
| WO (1) | WO2005107712A1 (enExample) |
Families Citing this family (173)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8658203B2 (en) | 2004-05-03 | 2014-02-25 | Merrimack Pharmaceuticals, Inc. | Liposomes useful for drug delivery to the brain |
| RU2424792C2 (ru) | 2004-05-03 | 2011-07-27 | Хермес Байесайенсиз, Инк. | Липосомы, используемые для доставки лекарственных средств |
| AP2255A (en) * | 2004-06-01 | 2011-07-21 | Yakult Honsha Kk | Irinotecan preparation. |
| US20080213183A1 (en) * | 2004-09-20 | 2008-09-04 | Marcel Bally | Free or Liposomal Gemcitabine Alone or in Combination with Free or Liposomal Idarubicin |
| AU2005304914B2 (en) * | 2004-11-05 | 2012-02-16 | Tekmira Pharmaceuticals Corporation | Compositions and methods for stabilizing liposomal camptothecin formulations |
| US8349359B2 (en) * | 2004-11-07 | 2013-01-08 | Your Energy Systems, LLC | Liposomal formulation for oral administration of glutathione (reduced) |
| WO2007076117A2 (en) * | 2005-12-22 | 2007-07-05 | Celator Pharmaceuticals, Inc. | Liposomal formulations comprising secondary and tertiary amines and methods for preparing thereof |
| DE102006015271A1 (de) * | 2006-04-01 | 2007-10-11 | Lohmann & Rauscher Gmbh & Co. Kg | Biguanidhaltige Liposomen |
| WO2008008523A1 (en) * | 2006-07-14 | 2008-01-17 | Regents Of The University Of Minnesota | COMPOUNDS THAT BIND α5β1 INTEGRIN AND METHODS OF USE |
| US20080118500A1 (en) * | 2006-11-16 | 2008-05-22 | Taiwan Liposome Company | Sustained releasing composition via local injection for treating eye diseases |
| CN101209243B (zh) | 2006-12-29 | 2010-12-08 | 石药集团中奇制药技术（石家庄）有限公司 | 一种脂质体药物及其制备方法 |
| FR2910812B1 (fr) * | 2006-12-29 | 2009-03-20 | Pierre Fabre Medicament Sa | Compositions pharmaceutiques injectables lyophilisees de derives hemi-synthetiques d'alcaloide de vinca stables a temperature ambiante |
| WO2008088037A1 (ja) * | 2007-01-18 | 2008-07-24 | National University Corporation Chiba University | 微粒子製剤 |
| WO2008114274A1 (en) * | 2007-03-19 | 2008-09-25 | Fresenius Kabi Onclology Ltd. | Proliposomal and liposomal compositions |
| US20100173014A1 (en) * | 2007-05-24 | 2010-07-08 | Nanosolutions, Llc | Methods of making and using nano scale particles |
| US20080305157A1 (en) * | 2007-06-08 | 2008-12-11 | University Of Maryland Office Of Technology Commercialization | Encapsulation and separation of charged organic solutes inside catanionic vesicles |
| EP2200613B1 (en) | 2007-09-21 | 2018-09-05 | The Johns Hopkins University | Phenazine derivatives and uses thereof |
| EP2240161A1 (en) * | 2008-01-04 | 2010-10-20 | Keller, Brian Charles | Enhanced delivery of antifungal agents |
| CN101536981B (zh) * | 2008-03-19 | 2010-11-17 | 上海医药工业研究院 | 一种盐酸可乐定多囊脂质体及其制备方法 |
| WO2009138806A1 (en) * | 2008-05-13 | 2009-11-19 | Dendrigen S.A. | Novel liposome cocktail formulations containing doxorubicin and the potent multidrug resistance inhibitor amiodarone |
| EP2123258A1 (en) | 2008-05-23 | 2009-11-25 | Liplasome Pharma A/S | Liposomes for drug delivery |
| US8790691B2 (en) | 2008-05-23 | 2014-07-29 | The University Of British Columbia | Modified drugs for use in liposomal nanoparticles |
| EP2331092B1 (en) | 2008-08-21 | 2014-03-19 | The Johns Hopkins University | Methods and compositions for administration of 3-halopyruvate and related compounds for the treatment of cancer |
| CN101565384B (zh) * | 2008-12-23 | 2012-12-26 | 南开大学 | 环糊精修饰单层石墨及其超分子复合物和制备方法及用途 |
| EP2601934A1 (en) * | 2009-01-22 | 2013-06-12 | Ludwig-Maximilians-Universität München | Vesicular phospholipid gels comprising proteinaceous substances |
| JP5588619B2 (ja) * | 2009-03-11 | 2014-09-10 | 一丸ファルコス株式会社 | ｐＨ応答性リポソーム |
| EP2415464B1 (en) * | 2009-03-30 | 2017-05-10 | Eisai R&D Management Co., Ltd. | Method for producing liposome composition |
| KR101495951B1 (ko) * | 2009-03-30 | 2015-02-25 | 에자이 알앤드디 매니지먼트 가부시키가이샤 | 리포솜 조성물 |
| JP5392707B2 (ja) * | 2009-03-31 | 2014-01-22 | 株式会社Ｎｔｔドコモ | 膜小胞分裂システム |
| WO2010135468A1 (en) * | 2009-05-19 | 2010-11-25 | Vivia Biotech S.L. | Methods for providing personalized medicine tests ex vivo for hematological neoplasms |
| DK177532B1 (en) | 2009-09-17 | 2013-09-08 | Bio Bedst Aps | Medical use of sPLA2 hydrolysable liposomes |
| ES2547698T3 (es) * | 2009-12-03 | 2015-10-08 | Jiangsu Hengrui Medicine Co., Ltd. | Liposoma de irinotecán o su clorhidrato y método de preparación del mismo |
| RU2429841C1 (ru) * | 2009-12-16 | 2011-09-27 | Государственное образовательное учреждение высшего профессионального образования "Московская государственная академия тонкой химической технологии имени М.В. Ломоносова" (МИТХТ имени М.В. Ломоносова) | Способ получения липосомальной формы изониазида |
| KR101000358B1 (ko) | 2010-04-29 | 2010-12-13 | 서울대학교산학협력단 | 인테그린 αⅤβ３ 결합성 지질 유도체 및 그를 포함하는 지질 나노입자 |
| CN105153307A (zh) | 2010-05-04 | 2015-12-16 | 梅里麦克制药股份有限公司 | 抗表皮生长因子受体(egfr)的抗体及其用途 |
| CN107261110A (zh) * | 2010-06-19 | 2017-10-20 | 健康科学西部大学 | Peg化脂质体包封的糖肽抗生素的新制剂 |
| WO2012061153A1 (en) | 2010-10-25 | 2012-05-10 | Medtronic Ardian Luxembourg S.A.R.L. | Devices, systems and methods for evaluation and feedback of neuromodulation treatment |
| JP2014503582A (ja) * | 2011-01-28 | 2014-02-13 | コーニンクレッカ フィリップス エヌ ヴェ | 親水性プロドラッグの局所放出用担体 |
| CA2834353A1 (en) * | 2011-04-26 | 2012-11-01 | Cedars-Sinai Medical Center | Liposomal vancomycin for the treatment of mrsa infections |
| EP2717856B1 (en) * | 2011-05-10 | 2016-11-23 | The Penn State Research Foundation | Ceramide anionic liposome compositions |
| US8691231B2 (en) | 2011-06-03 | 2014-04-08 | Merrimack Pharmaceuticals, Inc. | Methods of treatment of tumors expressing predominantly high affinity EGFR ligands or tumors expressing predominantly low affinity EGFR ligands with monoclonal and oligoclonal anti-EGFR antibodies |
| CN102805729A (zh) * | 2011-06-03 | 2012-12-05 | 齐鲁制药有限公司 | 一种长春氟宁脂质体制剂及其制备方法 |
| JP6219832B2 (ja) * | 2011-10-17 | 2017-10-25 | マサチューセッツ インスティテュート オブ テクノロジー | 細胞内送達 |
| JP2015514113A (ja) | 2012-04-02 | 2015-05-18 | メリマック ファーマシューティカルズ インコーポレーティッド | 単一特異性および二重特異性抗ｉｇｆ−１ｒおよび抗ｅｒｂｂ３抗体の用法および用量 |
| WO2013158803A1 (en) | 2012-04-17 | 2013-10-24 | Merrimack Pharmaceuticals, Inc. | Compositions and methods for non-invasive imaging |
| US9717724B2 (en) | 2012-06-13 | 2017-08-01 | Ipsen Biopharm Ltd. | Methods for treating pancreatic cancer using combination therapies |
| AU2013202947B2 (en) | 2012-06-13 | 2016-06-02 | Ipsen Biopharm Ltd. | Methods for treating pancreatic cancer using combination therapies comprising liposomal irinotecan |
| KR101949125B1 (ko) | 2012-07-04 | 2019-02-18 | 고려대학교 산학협력단 | ｐＨ 민감성 형광 발광의 폴리디아세틸렌 리포좀 및 이를 포함하는 약물 전달체 |
| SG10201701063WA (en) * | 2012-08-10 | 2017-04-27 | Taiho Pharmaceutical Co Ltd | Stable oxaliplatin-encapsulating liposome aqueous dispersion and method for stabilizing same |
| EP3470061A1 (en) | 2012-11-20 | 2019-04-17 | Spectrum Pharmaceuticals, Inc. | Improved method for the preparation of a dosage of liposome encapsulated vincristine for therapeutic use |
| RU2514000C1 (ru) * | 2012-12-14 | 2014-04-27 | Общество с ограниченной ответственностью "Уральский центр биофармацевтических технологий" | Липосомальная композиция и способ ее получения |
| US20140220110A1 (en) | 2013-02-01 | 2014-08-07 | Zoneone Pharma, Inc. | Remote loading of sparingly water-soluble drugs into liposomes |
| EP2964201B1 (en) | 2013-03-05 | 2024-02-14 | The Regents of the University of California | Lipid bilayer coated mesoporous silica nanoparticles with a high loading capacity for one or more anticancer agents |
| US9993427B2 (en) * | 2013-03-14 | 2018-06-12 | Biorest Ltd. | Liposome formulation and manufacture |
| US10220095B2 (en) | 2013-03-15 | 2019-03-05 | Taiwan Liposome Company, Ltd | Controlled drug release liposome compositions and methods thereof |
| SG11201507110WA (en) * | 2013-03-15 | 2015-10-29 | Taiwan Liposome Co Ltd | Engineering a control drug release profile via liposome composition in both aqueous andnon-aqueous compartments |
| WO2014167327A1 (en) * | 2013-04-09 | 2014-10-16 | Cresset Biomolecular Discovery Ltd | The treatment of inflammatory disorders |
| ES2822584T3 (es) | 2013-05-03 | 2021-05-04 | Univ California | Inducción de dinucleótidos cíclicos del interferón tipo I |
| US20160220675A1 (en) | 2013-09-11 | 2016-08-04 | Glenn Abrahmsohn | Hypertonic antimicrobial therapeutic compositions |
| US20160303264A1 (en) * | 2013-10-23 | 2016-10-20 | Merrimack Pharmaceuticals, Inc. | Liposomes useful for non-invasive imaging and drug delivery |
| US9592198B2 (en) * | 2013-10-28 | 2017-03-14 | University Of Maryland, College Park | Microfluidic liposome synthesis, purification and active drug loading |
| EP3107551B1 (en) | 2014-02-18 | 2020-10-28 | Glenn Abrahmsohn | Compositions comprising bicarbonate and calcium salts for pain relief without numbness |
| JP6263609B2 (ja) * | 2014-04-30 | 2018-01-17 | 富士フイルム株式会社 | リポソーム組成物及びその製造方法 |
| DK3138555T3 (da) * | 2014-04-30 | 2020-12-14 | Fujifilm Corp | Liposomsammensætning og fremgangsmåde til fremstilling heraf |
| EP3138558B1 (en) | 2014-04-30 | 2023-06-07 | FUJIFILM Corporation | Liposome composition and production method therefor |
| MA39599A (fr) | 2014-05-14 | 2016-10-05 | Merrimack Pharmaceuticals Inc | Dosage et administration d'agents thérapeutiques anti-egfr |
| US10004759B2 (en) | 2014-08-04 | 2018-06-26 | Zoneone Pharma, Inc. | Remote loading of sparingly water-soluble drugs into lipid vesicles |
| WO2016048242A1 (en) * | 2014-09-24 | 2016-03-31 | Nanyang Technological University | Sustained timolol maleate delivery from liposomes for glaucoma therapy and ocular hypertension |
| JP7113619B2 (ja) | 2014-12-09 | 2022-08-05 | イプセン バイオファーム リミティド | リポソーマルイリノテカンによる乳がんの治療 |
| US11318131B2 (en) | 2015-05-18 | 2022-05-03 | Ipsen Biopharm Ltd. | Nanoliposomal irinotecan for use in treating small cell lung cancer |
| EP3302435B1 (en) * | 2015-05-26 | 2023-03-08 | Plumb Pharmaceuticals, Inc. | Liposome loading |
| US9855216B2 (en) * | 2015-05-27 | 2018-01-02 | Ghasem Amoabediny | Targeted nano-liposome co-entrapping anti-cancer drugs |
| TWI678213B (zh) | 2015-07-22 | 2019-12-01 | 美商史倍壯製藥公司 | 用於長春新鹼硫酸鹽脂質體注射之即可使用的調配物 |
| HK1257216A1 (zh) | 2015-08-20 | 2019-10-18 | 益普生生物制药有限公司 | 使用脂质体伊立替康和parp抑制剂用於癌症治疗的组合疗法 |
| WO2017034418A1 (en) * | 2015-08-21 | 2017-03-02 | Reynolds John Noble James | Acoustic driven drug delivery systems |
| BR112018002941B1 (pt) | 2015-08-21 | 2023-12-05 | Ipsen Biopharm Ltd | Uso de irinotecano lipossomal, oxaliplatina, leucovorina e 5- fluorouracil no tratamento de primeira linha de adenocarcinoma metastático do pâncreas |
| WO2017041051A1 (en) | 2015-09-04 | 2017-03-09 | Sqz Biotechnologies Company | Intracellular delivery of biomolecules to cells comprising a cell wall |
| US10894044B2 (en) | 2015-09-16 | 2021-01-19 | Board Of Regents, The University Of Texas System | Combination of topoisomerase-I inhibitors with immunotherapy in the treatment of cancer |
| CN105153339B (zh) * | 2015-10-13 | 2017-10-24 | 浙江大学 | 一种氧化响应去正电荷的阳离子聚合物、制备方法和应用 |
| JP6924431B2 (ja) * | 2015-10-13 | 2021-08-25 | 株式会社ケーナインラボ | ヒトを除く哺乳動物への薬剤の投与方法 |
| US20170319573A1 (en) * | 2015-10-16 | 2017-11-09 | Ipsen Biopharm Ltd. | Stabilizing Camptothecin Pharmaceutical Compositions |
| BR112018006922B1 (pt) | 2015-10-16 | 2023-11-21 | Ipsen Biopharm Ltd | Composições de irinotecano lipossômico estabilizado para armazenamento |
| EP3372223B1 (en) * | 2015-11-02 | 2024-04-17 | FUJIFILM Corporation | Liposome composition and method for producing same |
| ES2869283T3 (es) | 2015-11-02 | 2021-10-25 | Fujifilm Corp | Agente terapéutico antitumoral que contiene composición de liposoma de gemcitabina y kit |
| EP3370712B1 (en) | 2015-11-06 | 2025-02-19 | The Johns Hopkins University | 3-bromopyruvate for treating liver fibrosis |
| EP3373910B1 (en) | 2015-11-10 | 2023-07-12 | Children's Research Institute, Children's National Medical Center | Echinomycin formulation, method of making and method of use thereof |
| CN105287264B (zh) * | 2015-11-25 | 2018-06-19 | 上海赢嘉实业有限公司 | 一种包封芳香油复合物的脂质体的制备方法和用途 |
| US20180271998A1 (en) | 2015-12-04 | 2018-09-27 | Merrimack Pharmaceuticals, Inc. | Disulfide-stabilized fabs |
| CN105496992A (zh) * | 2015-12-08 | 2016-04-20 | 青岛正大海尔制药有限公司 | 氨溴索沙丁胺醇脂质固体分散体 |
| EP4218739A3 (en) * | 2016-01-08 | 2023-08-09 | The Regents of The University of California | Mesoporous silica nanoparticles with lipid bilayer coating for cargo delivery |
| JP2019501225A (ja) * | 2016-01-11 | 2019-01-17 | メリマック ファーマシューティカルズ インコーポレーティッド | Ｂ細胞リンパ腫２（ｂｃｌ−２）及び関連タンパク質の阻害 |
| CN108697811B (zh) | 2016-01-11 | 2023-04-07 | 梅里麦克制药股份有限公司 | 抑制共济失调毛细血管扩张和Rad3相关蛋白(ATR) |
| WO2017142876A1 (en) * | 2016-02-15 | 2017-08-24 | University Of Georgia Research Foundation, Inc. | lPA-3-LOADED LIPOSOMES AND METHODS OF USE THEREOF |
| US10406117B2 (en) * | 2016-02-15 | 2019-09-10 | Kemin Industries, Inc. | Water soluble lipophilic materials |
| JP2019508434A (ja) | 2016-03-16 | 2019-03-28 | メリマック ファーマシューティカルズ インコーポレーティッド | エフリン受容体Ａ２（ＥｐｈＡ２）標的ドセタキセル産生ナノリポソーム組成物 |
| CA3016383A1 (en) | 2016-03-16 | 2017-09-21 | Merrimack Pharmaceuticals, Inc | Treating ephrin receptor a2 (epha2) positive cancer with targeted docetaxel-generating nano-liposome compositions |
| EP3449921B1 (en) | 2016-04-28 | 2023-05-31 | Eisai R&D Management Co., Ltd. | Eribulin for inhibiting tumor growth |
| KR102430856B1 (ko) | 2016-05-03 | 2022-08-08 | 에스큐지 바이오테크놀로지스 컴퍼니 | 관용을 유도하는 생체분자의 세포내 전달 |
| MA45046A (fr) * | 2016-05-18 | 2019-03-27 | Ipsen Biopharm Ltd | Irinotécan nanoliposomal utilisé dans le traitement du cancer bronchique à petites cellules |
| US9655847B1 (en) * | 2016-07-18 | 2017-05-23 | National Guard Health Affairs | Therapeutic liposome and method of treating a subject having cancer |
| US10583083B1 (en) | 2016-08-10 | 2020-03-10 | Verily Life Sciences Llc | ROS-responsive multilamellar liposomal vesicles for targeting inflammatory macrophages |
| US10517823B1 (en) | 2016-08-10 | 2019-12-31 | Verily Life Sciences Llc | ROS—responsive liposomes for specific targeting |
| US20180236098A1 (en) | 2016-08-12 | 2018-08-23 | L.E.A.F. Holdings Group Llc | Alpha and gamma-d polyglutamated antifolates and uses thereof |
| EP3496757A4 (en) | 2016-08-12 | 2020-04-15 | L.E.A.F Holdings Group LLC | POLYGLUTAMATE ANTIFOLATES AND USES THEREOF. |
| EP3508268B1 (en) * | 2016-08-31 | 2023-10-25 | Kewpie Corporation | Egg yolk phospholipid composition and fat emulsion and lipolysis formulation using egg yolk phospholipid composition |
| CA3036235A1 (en) * | 2016-09-09 | 2018-03-15 | Irisys, Inc. | Lipsomal anticancer compositions |
| CN110402163A (zh) | 2016-11-02 | 2019-11-01 | 易普森生物制药有限公司 | 使用包括脂质体伊立替康、奥沙利铂、5-氟尿嘧啶(和甲酰四氢叶酸)的组合疗法治疗胃癌 |
| US10800817B2 (en) * | 2016-12-19 | 2020-10-13 | Morehouse School Of Medicine | Compositions and methods for treating diseases by inhibiting exosome release |
| AU2017258901A1 (en) | 2016-12-30 | 2018-07-19 | Allarity Therapeutics Europe ApS | Methods for predicting drug responsiveness in cancer patients |
| SG10202107836SA (en) * | 2017-01-18 | 2021-08-30 | Temasek Life Sciences Laboratory Ltd | Hyperstabilized liposomes increase targeting of mitotic cells |
| WO2018218052A1 (en) * | 2017-05-24 | 2018-11-29 | Northwestern University | Nanoparticle-lipid composite carriers and uses thereof |
| CN108926719B (zh) * | 2017-05-25 | 2020-09-01 | 北京格瑞特森生物医药科技有限公司 | 用c(RGD-ACP-K)修饰的长循环脂质体 |
| WO2019054220A1 (ja) * | 2017-09-12 | 2019-03-21 | オルガノ株式会社 | 電解液の精製装置および精製方法 |
| CN110998955B (zh) * | 2017-09-12 | 2023-04-25 | 奥加诺株式会社 | 电解液的精制装置和精制方法 |
| CN108047494B (zh) * | 2017-11-15 | 2019-11-08 | 四川大学 | 植酸铵盐阻燃剂及其制备方法和用以制备的阻燃增韧聚乳酸材料 |
| CN109364025A (zh) * | 2017-11-17 | 2019-02-22 | 和龙 | 脂质体组合物、其制备方法及其应用 |
| US12383499B2 (en) | 2018-01-01 | 2025-08-12 | The Regents Of The University Of California | Scale up synthesis of silicasome nanocarriers |
| EP3749317A4 (en) | 2018-02-07 | 2022-06-22 | L.E.A.F Holdings Group LLC | PEMETREXED ALPHA-POLYGLUTAMATE AND ASSOCIATED USES |
| US12310966B2 (en) * | 2018-02-07 | 2025-05-27 | L.E.A.F. Holdings Group Llc | Alpha polyglutamated aminopterin and uses thereof |
| JP7491573B2 (ja) * | 2018-02-07 | 2024-05-28 | エル．イー．エー．エフ． ホールディングス グループ エルエルシー | アルファポリグルタミン酸化メトトレキセートおよびその使用 |
| WO2019157145A1 (en) * | 2018-02-07 | 2019-08-15 | L.E.A.F. Holdings Group Llc | Gamma polyglutamated pemetrexed and uses thereof |
| US12246019B2 (en) * | 2018-02-07 | 2025-03-11 | L.E.A.F. Holdings Group Llc | Alpha polyglutamated lometrexol and uses thereof |
| US12246015B2 (en) | 2018-02-07 | 2025-03-11 | L.E.A.F. Holdings Group Llc | Alpha polyglutamated raltitrexed and uses thereof |
| US12220431B2 (en) | 2018-02-07 | 2025-02-11 | L.E.A.F. Holdings Group Llc | Gamma polyglutamated antifolates and uses thereof |
| US12076402B2 (en) | 2018-02-07 | 2024-09-03 | L.E.A.F. Holdings Group Llc | Alpha polyglutamated antifolates and uses thereof |
| EP3749318A4 (en) | 2018-02-07 | 2022-07-06 | L.E.A.F Holdings Group LLC | GAMMA-POLYGLUTAMATED RALTITREXED AND ITS USES |
| US11730738B2 (en) | 2018-02-07 | 2023-08-22 | L.E.A.F. Holdings Group Llc | Alpha polyglutamated pralatrexate and uses thereof |
| CA3090506A1 (en) | 2018-02-07 | 2019-08-15 | L.E.A.F. Holdings Group Llc | Alpha polyglutamated tetrahydrofolates and uses thereof |
| EP3752158A4 (en) | 2018-02-14 | 2022-03-09 | L.E.A.F Holdings Group LLC | GAMMA-POLYGLUTAMATED AMINOPTERINE AND USES THEREOF |
| WO2019160735A1 (en) | 2018-02-14 | 2019-08-22 | L.E.A.F. Holdings Group Llc | Gamma polyglutamated tetrahydrofolates and uses thereof |
| CA3090989A1 (en) * | 2018-02-14 | 2019-08-22 | L.E.A.F. Holdings Group Llc | Gamma polyglutamated methotrexate and uses thereof |
| WO2019160734A1 (en) | 2018-02-14 | 2019-08-22 | L.E.A.F. Holdings Group Llc | Gamma polyglutamated lometrexol and uses thereof |
| CA3090753A1 (en) * | 2018-02-14 | 2019-08-22 | L.E.A.F. Holdings Group Llc | Gamma polyglutamated pralatrexate and uses thereof |
| CN112312895B (zh) * | 2018-06-20 | 2023-05-09 | 富士胶片株式会社 | 包含内含药物的脂质体组合物及免疫检查点抑制剂的组合医药 |
| JP7364561B2 (ja) | 2018-06-20 | 2023-10-18 | 富士フイルム株式会社 | ゲムシタビンを内包するリポソーム組成物および免疫チェックポイント阻害剤を含む組合せ医薬 |
| WO2020023436A1 (en) * | 2018-07-23 | 2020-01-30 | Campbell Robert B | Cell membrane lipid-extracted nanoparticles (clens) for selective targeting, image analysis and cancer therapy |
| CN112512508A (zh) | 2018-07-24 | 2021-03-16 | 台湾微脂体股份有限公司 | 含有治疗失智症的治疗剂的缓释药物组合物及其用途 |
| CN112512509A (zh) | 2018-08-02 | 2021-03-16 | 台湾微脂体股份有限公司 | 含有治疗抑郁症或焦虑症的治疗剂的缓释组合物及其用途 |
| US12285524B2 (en) * | 2018-08-08 | 2025-04-29 | Taiwan Liposome Co., Ltd. | Sustained-release pharmaceutical compositions comprising an antipsychotic drug and uses thereof |
| CN112789032A (zh) * | 2018-10-01 | 2021-05-11 | 富士胶片株式会社 | 包含内含药物的脂质体组合物及铂制剂的组合医药 |
| US12274785B2 (en) | 2018-10-17 | 2025-04-15 | Taiwan Liposome Co., Ltd. | Sustained-release pharmaceutical compositions comprising an immunomodulating agent and uses thereof |
| WO2020102605A1 (en) * | 2018-11-15 | 2020-05-22 | The Regents Of The University Of California | Vesicle-coated fibers and methods of making and using |
| CN109528654B (zh) * | 2018-12-14 | 2021-04-23 | 沈阳药科大学 | 一种盐酸伊立替康和盐酸阿霉素共载脂质体及其制备方法 |
| CN109528655A (zh) * | 2018-12-18 | 2019-03-29 | 沈阳药科大学 | 一种双载药脂质体及其制备和应用 |
| JP7610773B2 (ja) | 2019-02-28 | 2025-01-09 | ステムセル テクノロジーズ カナダ インコーポレーテッド | 免疫応答を改変するためのｐｂｍｃへの生体分子の送達 |
| KR20210149791A (ko) | 2019-04-08 | 2021-12-09 | 에스큐지 바이오테크놀로지스 컴퍼니 | 페이로드를 세포 내로 전달하기 위한 시스템에서 이용하기 위한 카트리지 |
| WO2020242996A1 (en) * | 2019-05-28 | 2020-12-03 | Nevakar Inc. | Vancomycin liposome compositions and methods |
| EP3753549A1 (en) * | 2019-06-20 | 2020-12-23 | InnoMedica Holding AG | Liposomal doxorubicin formulation, method for producing a liposomal doxorubicin formulation and use of a liposomal doxorubicin formulation as a medicament |
| CN114144198A (zh) * | 2019-07-16 | 2022-03-04 | 科斯塔治疗公司 | 膜脂包覆的纳米颗粒的制备方法 |
| US12036204B2 (en) | 2019-07-26 | 2024-07-16 | Eisai R&D Management Co., Ltd. | Pharmaceutical composition for treating tumor |
| US11083705B2 (en) | 2019-07-26 | 2021-08-10 | Eisai R&D Management Co., Ltd. | Pharmaceutical composition for treating tumor |
| US20230139328A1 (en) * | 2020-03-12 | 2023-05-04 | Aphios Corporation | Dosage forms for improving organ transplantation, graft versus host disease and stem cells transplants |
| US11555033B2 (en) | 2020-06-18 | 2023-01-17 | Akagera Medicines, Inc. | Oxazolidinone compounds, liposome compositions comprising oxazolidinone compounds and method of use thereof |
| US20240173257A1 (en) * | 2020-07-07 | 2024-05-30 | THERMOSOME GmbH | Liposome formulations |
| CN112190715B (zh) * | 2020-10-21 | 2022-09-30 | 中国人民解放军军事科学院军事医学研究院 | 纳米药物、其制备方法及医药应用 |
| US11591544B2 (en) | 2020-11-25 | 2023-02-28 | Akagera Medicines, Inc. | Ionizable cationic lipids |
| US11058637B1 (en) * | 2020-11-25 | 2021-07-13 | King Abdulaziz University | Surface-modified emulsomes for intranasal delivery of drugs |
| WO2022153211A1 (en) | 2021-01-13 | 2022-07-21 | Sun Pharma Advanced Research Company Limited | Liposomal composition of a camptothecin derivative |
| WO2022171777A1 (en) | 2021-02-12 | 2022-08-18 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Method for prognosis and treating a patient suffering from cancer |
| JP2024526791A (ja) * | 2021-07-16 | 2024-07-19 | セレーター ファーマシューティカルズ インコーポレイテッド | リポソーム製剤の調製方法 |
| WO2023029041A1 (zh) * | 2021-09-06 | 2023-03-09 | 北京茵诺医药科技有限公司 | 靶向动脉粥样硬化脂质体纳米载体递送系统及其制备方法 |
| TW202317070A (zh) * | 2021-09-30 | 2023-05-01 | 大陸商上海濟煜醫藥科技有限公司 | 酒石酸長春瑞濱脂質體及其原料組合物、製備方法和應用 |
| EP4169928A1 (en) * | 2021-10-25 | 2023-04-26 | Sandoz Ag | Process for the preparation of sucrose octasulfate octakistriethylammonium salt (tasos) powder and uses thereof |
| CN114099691A (zh) * | 2021-11-22 | 2022-03-01 | 京东方科技集团股份有限公司 | 一种人造细胞及其制备方法 |
| WO2023112038A1 (en) | 2021-12-15 | 2023-06-22 | Immunyx Pharma Ltd. | Neutrophil exocytosis inhibitors |
| CN114306243B (zh) * | 2022-01-07 | 2023-03-28 | 中国人民解放军空军军医大学 | 一种靶向梭型柔性脂质体水凝胶及其制备方法和应用 |
| CN114469865B (zh) * | 2022-03-17 | 2023-09-22 | 中国医学科学院输血研究所 | 一种与血细胞膜结合的脂质体药物载体及其制备方法和用途 |
| EP4467129A4 (en) * | 2022-03-31 | 2025-10-29 | Eisai R&D Man Co Ltd | LIPOSOME COMPOSITION AND PHARMACEUTICAL COMPOSITION CONTAINING LIPOSOME |
| AU2023275780A1 (en) | 2022-05-25 | 2024-12-05 | Akagera Medicines, Inc. | Lipid nanoparticles for delivery of nucleic acids and methods of use thereof |
| US12194037B2 (en) * | 2023-01-06 | 2025-01-14 | Microneb Tech Holdings, Inc. | Apparatus, methods, and systems for providing pharmaceutical compositions and administering medications to patients |
| WO2024199424A1 (zh) * | 2023-03-30 | 2024-10-03 | 上海济煜医药科技有限公司 | 一种磷脂组合物及其制备方法及含氮化合物的应用 |
| CN116687861A (zh) * | 2023-06-07 | 2023-09-05 | 上海其胜生物制剂有限公司 | 一种具有细胞调节功能的大尺寸脂质体及其制备方法与应用 |
| CN116602923A (zh) * | 2023-07-20 | 2023-08-18 | 暨南大学附属第一医院（广州华侨医院） | 一种用于关节炎治疗的靶向仿生纳米治疗载体系统 |
Family Cites Families (129)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES473087A1 (es) * | 1977-09-06 | 1979-04-16 | Studiengesellschaft Kohle Mbh | Procedimiento para la preparacion de eritrocitos intactos modificados. |
| US4192869A (en) * | 1977-09-06 | 1980-03-11 | Studiengesellschaft Kohle Mbh. | Controlled improvement of the O2 release by intact erythrocytes with lipid vesicles |
| DE2740053A1 (de) * | 1977-09-06 | 1979-05-03 | Klaus Prof Dr Med Gersonde | Verwendung von allosterischen effektoren mit hilfe von lipidvesikeln ueber eine irreversible inkorporierung zwecks verbesserter o tief 2 -entladung des haemoglobins in erythrozyten |
| US4397846A (en) | 1981-05-15 | 1983-08-09 | Murray Weiner | Storage-stable lipid vesicles and method of preparation |
| US5059591B1 (en) * | 1983-05-26 | 2000-04-25 | Liposome Co Inc | Drug preparations of reduced toxicity |
| JPS6019790A (ja) | 1983-07-14 | 1985-01-31 | Yakult Honsha Co Ltd | 新規なカンプトテシン誘導体 |
| IL72420A (en) | 1983-07-22 | 1987-10-30 | Hoffmann La Roche | Aqueous vitamin e solutions and their manufacture |
| US5077056A (en) * | 1984-08-08 | 1991-12-31 | The Liposome Company, Inc. | Encapsulation of antineoplastic agents in liposomes |
| US5736155A (en) * | 1984-08-08 | 1998-04-07 | The Liposome Company, Inc. | Encapsulation of antineoplastic agents in liposomes |
| US4755388A (en) | 1984-11-09 | 1988-07-05 | The Regents Of The University Of California | Liposome-encapsulated 5-fluoropyrimidines and methods for their use |
| DE3634392A1 (de) | 1986-10-09 | 1988-04-14 | Knoll Ag | Verwendung polysulfatierter niedermolekularer dextransulfate |
| MX9203808A (es) * | 1987-03-05 | 1992-07-01 | Liposome Co Inc | Formulaciones de alto contenido de medicamento: lipido, de agentes liposomicos-antineoplasticos. |
| JPH0720857B2 (ja) | 1988-08-11 | 1995-03-08 | テルモ株式会社 | リポソームおよびその製法 |
| IL91664A (en) | 1988-09-28 | 1993-05-13 | Yissum Res Dev Co | Ammonium transmembrane gradient system for efficient loading of liposomes with amphipathic drugs and their controlled release |
| US5043165A (en) * | 1988-12-14 | 1991-08-27 | Liposome Technology, Inc. | Novel liposome composition for sustained release of steroidal drugs |
| US5043164A (en) | 1989-01-17 | 1991-08-27 | The University Of Tennessee Research Corporation | Blood-stable, cholesterol-free liposomes |
| US4960790A (en) | 1989-03-09 | 1990-10-02 | University Of Kansas | Derivatives of taxol, pharmaceutical compositions thereof and methods for the preparation thereof |
| US5618798A (en) * | 1989-04-20 | 1997-04-08 | Bar-Shalom; Daniel | Use of sucralfate to treat baldness |
| ZA902710B (en) | 1989-05-22 | 1991-12-24 | Univ Georgia Res Found | Enzyme luminescence assay |
| US5013556A (en) | 1989-10-20 | 1991-05-07 | Liposome Technology, Inc. | Liposomes with enhanced circulation time |
| US5264618A (en) | 1990-04-19 | 1993-11-23 | Vical, Inc. | Cationic lipids for intracellular delivery of biologically active molecules |
| PL296382A1 (en) * | 1991-02-02 | 1993-11-02 | Nika Health Products Ltd Li Li | Artificial membrane beads containing functionally active peptides responsible for fusion as a drug administering system |
| US5498420A (en) | 1991-04-12 | 1996-03-12 | Merz & Co. Gmbh & Co. | Stable small particle liposome preparations, their production and use in topical cosmetic, and pharmaceutical compositions |
| ES2078034T3 (es) | 1991-07-03 | 1995-12-01 | Vestar Inc | Tecnica de carga para preparar liposomas que contienen farmacos. |
| US5281237A (en) * | 1992-09-25 | 1994-01-25 | Gimpelson Richard J | Surgical stitching device and method of use |
| US5552156A (en) | 1992-10-23 | 1996-09-03 | Ohio State University | Liposomal and micellular stabilization of camptothecin drugs |
| US5395619A (en) | 1993-03-03 | 1995-03-07 | Liposome Technology, Inc. | Lipid-polymer conjugates and liposomes |
| US6350853B1 (en) | 1993-04-26 | 2002-02-26 | Peter E. Nielsen | Conjugated peptide nucleic acids having enhanced cellular uptake |
| DE4320597A1 (de) | 1993-06-22 | 1995-01-05 | Heinz C Prof Dr Dr Schroeder | Verwendung von Polyphosphaten zur antiviralen Therapie und als Immunmodulatoren |
| US6743917B2 (en) * | 1993-06-30 | 2004-06-01 | University Of Pittsburgh | Camptothecin analogs and methods of preparation thereof |
| US5994341A (en) | 1993-07-19 | 1999-11-30 | Angiogenesis Technologies, Inc. | Anti-angiogenic Compositions and methods for the treatment of arthritis |
| US5534241A (en) * | 1993-07-23 | 1996-07-09 | Torchilin; Vladimir P. | Amphipathic polychelating compounds and methods of use |
| US5538954A (en) * | 1994-06-24 | 1996-07-23 | A/S Dumex (Dumex Ltd.) | Salts of tetracyclines |
| GB9323588D0 (en) | 1993-11-16 | 1994-01-05 | Cortecs Ltd | Hydrophobic preparation |
| DE69528355T2 (de) * | 1994-02-04 | 2003-05-15 | Lipocore Holding Ab Stockholm | Doppelschicht-zusammensetzungen aus digalactosyldiacylglycerol enthaltendem galactolipid |
| US6312719B1 (en) | 1994-03-04 | 2001-11-06 | The University Of British Columbia | Liposome compositions and methods for the treatment of atherosclerosis |
| US6110481A (en) * | 1994-03-04 | 2000-08-29 | Trustees Of The Stevens Institute Of Technology | Controlled release device based on aqueous-organic partitioning in porous membranes |
| US5783568A (en) * | 1994-06-10 | 1998-07-21 | Sugen, Inc. | Methods for treating cancer and other cell proliferative diseases |
| US5543152A (en) | 1994-06-20 | 1996-08-06 | Inex Pharmaceuticals Corporation | Sphingosomes for enhanced drug delivery |
| US5741516A (en) | 1994-06-20 | 1998-04-21 | Inex Pharmaceuticals Corporation | Sphingosomes for enhanced drug delivery |
| US5820873A (en) | 1994-09-30 | 1998-10-13 | The University Of British Columbia | Polyethylene glycol modified ceramide lipids and liposome uses thereof |
| US6214388B1 (en) | 1994-11-09 | 2001-04-10 | The Regents Of The University Of California | Immunoliposomes that optimize internalization into target cells |
| GB9424902D0 (en) | 1994-12-09 | 1995-02-08 | Cortecs Ltd | Solubilisation Aids |
| AU4981896A (en) | 1995-02-14 | 1996-09-04 | Sequus Pharmaceuticals, Inc. | Liposome composition and method for administering liposome-loadable drugs |
| US5800833A (en) * | 1995-02-27 | 1998-09-01 | University Of British Columbia | Method for loading lipid vesicles |
| US5858397A (en) | 1995-10-11 | 1999-01-12 | University Of British Columbia | Liposomal formulations of mitoxantrone |
| DE19605024A1 (de) * | 1996-01-31 | 1997-08-07 | Schering Ag | Neue selektive Taxane, Verfahren zu ihrer Herstellung und ihre pharmazeutische Verwendung |
| US5756475A (en) | 1996-01-31 | 1998-05-26 | Nisshin Flour Milling Co., Ltd. | Isoprene derivatives |
| US6441025B2 (en) | 1996-03-12 | 2002-08-27 | Pg-Txl Company, L.P. | Water soluble paclitaxel derivatives |
| CA2252055C (en) | 1996-04-11 | 2007-01-16 | The University Of British Columbia | Fusogenic liposomes |
| US5997899A (en) | 1996-10-01 | 1999-12-07 | Skyepharma Inc. | Method for producing liposomes with increased percent of compound encapsulated |
| US6056973A (en) | 1996-10-11 | 2000-05-02 | Sequus Pharmaceuticals, Inc. | Therapeutic liposome composition and method of preparation |
| EP0949906A4 (en) * | 1996-10-22 | 2004-11-24 | Hermes Biosciences Inc | LIPOSOMES LOADED WITH ACTIVE SUBSTANCE AND THEIR PRODUCTION METHOD |
| US6210707B1 (en) * | 1996-11-12 | 2001-04-03 | The Regents Of The University Of California | Methods of forming protein-linked lipidic microparticles, and compositions thereof |
| EP0944311B1 (en) | 1996-11-19 | 2006-03-01 | Georgetown University | Method for antagonizing HEREGUlin or its receptor and use for the inhibition of cancer cells |
| US5827533A (en) | 1997-02-06 | 1998-10-27 | Duke University | Liposomes containing active agents aggregated with lipid surfactants |
| JP4386470B2 (ja) * | 1997-05-15 | 2009-12-16 | ユニバーシティ・オブ・ワシントン | アルツハイマー病および他のアミロイド症のための組成物および方法 |
| JP2000516641A (ja) * | 1997-07-02 | 2000-12-12 | エスディージー インコーポレイテッド | 診断および治療用途の目標指向性リポソーム構成物 |
| US6316612B1 (en) | 1997-08-22 | 2001-11-13 | Ribozyme Pharmaceuticals, Inc. | Xylofuranosly-containing nucleoside phosphoramidites and polynucleotides |
| US6083923A (en) | 1997-10-31 | 2000-07-04 | Isis Pharmaceuticals Inc. | Liposomal oligonucleotide compositions for modulating RAS gene expression |
| US6787132B1 (en) | 1997-12-04 | 2004-09-07 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Combined chemo-immunotherapy with liposomal drugs and cytokines |
| US7244826B1 (en) | 1998-04-24 | 2007-07-17 | The Regents Of The University Of California | Internalizing ERB2 antibodies |
| RU2130771C1 (ru) * | 1998-06-01 | 1999-05-27 | Автушенко Сергей Сергеевич | Способ получения липосомальных препаратов |
| US6200598B1 (en) | 1998-06-18 | 2001-03-13 | Duke University | Temperature-sensitive liposomal formulation |
| US6726925B1 (en) | 1998-06-18 | 2004-04-27 | Duke University | Temperature-sensitive liposomal formulation |
| GB9813100D0 (en) | 1998-06-18 | 1998-08-19 | Secr Defence | Method of forming liposomes |
| AU1678900A (en) | 1998-08-11 | 2000-03-06 | All India Institute Of Medical Sciences | A novel liposomal formulation useful in treatment of cancer and other proliferation diseases |
| CA2340118C (en) | 1998-08-12 | 2009-01-13 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Liposomal bupivacaine compositions prepared using an ammonium sulfate gradient |
| CA2346879A1 (en) | 1998-09-16 | 2000-04-27 | Alza Corporation | Liposome-entrapped topoisomerase inhibitors |
| US6291676B1 (en) * | 1999-03-03 | 2001-09-18 | University Of Kentucky Research Foundation | Water-soluble derivatives of camptothecin/homocamptothecin |
| US7311924B2 (en) | 1999-04-01 | 2007-12-25 | Hana Biosciences, Inc. | Compositions and methods for treating cancer |
| JP2002543134A (ja) | 1999-04-29 | 2002-12-17 | アルザ・コーポレーション | 薬物保持率を改善するためのリポソーム組成物 |
| US6720001B2 (en) | 1999-10-18 | 2004-04-13 | Lipocine, Inc. | Emulsion compositions for polyfunctional active ingredients |
| US6511676B1 (en) * | 1999-11-05 | 2003-01-28 | Teni Boulikas | Therapy for human cancers using cisplatin and other drugs or genes encapsulated into liposomes |
| US20020049176A1 (en) * | 1999-11-10 | 2002-04-25 | Anderson Christen M. | Modulation of mitochondrial mass and function for the treatment of diseases and for target and drug discovery |
| ATE341310T1 (de) * | 2000-02-04 | 2006-10-15 | Lipoxen Technologies Ltd | Dehydratisierungs-/rehydratisierungsverfahren zur herstellung von liposome |
| US6545010B2 (en) | 2000-03-17 | 2003-04-08 | Aventis Pharma S.A. | Composition comprising camptothecin or a camptothecin derivative and a platin derivative for the treatment of cancer |
| JP4679028B2 (ja) | 2000-05-15 | 2011-04-27 | セルジーン コーポレイション | 結腸直腸癌を治療するための組成物および方法 |
| AU7038501A (en) | 2000-06-30 | 2002-01-14 | Inex Pharmaceuticals Corp | Liposomal antineoplastic drugs and uses thereof |
| US6486320B2 (en) | 2000-09-15 | 2002-11-26 | Aventis Pharma S.A. | Preparation of camptothecin and of its derivatives |
| WO2002036073A2 (en) | 2000-11-02 | 2002-05-10 | Smithkline Beecham Corporation | Receptor antagonist-lipid conjugates and delivery vehicles containing same |
| US20030064948A1 (en) | 2001-02-08 | 2003-04-03 | Alfred Fahr | Invasomes for therapy of disorders, their preparation and use |
| JP2004525138A (ja) * | 2001-03-26 | 2004-08-19 | アルザ・コーポレーシヨン | 治療剤の改良された細胞内送達のためのリポソーム組成物 |
| US7219016B2 (en) | 2001-04-20 | 2007-05-15 | Yale University | Systems and methods for automated analysis of cells and tissues |
| WO2003030864A1 (en) * | 2001-05-29 | 2003-04-17 | Neopharm, Inc. | Liposomal formulation of irinotecan |
| AU2002331481B2 (en) * | 2001-10-03 | 2008-04-24 | Celator Pharmaceuticals, Inc. | Liposome loading with metal ions |
| US7850990B2 (en) | 2001-10-03 | 2010-12-14 | Celator Pharmaceuticals, Inc. | Compositions for delivery of drug combinations |
| ITBO20010610A1 (it) * | 2001-10-05 | 2003-04-05 | Haworth S P A | Dispositivo per la connessione di gambe ad elementi di arredamento, ed elemento di arredamento comprendente tale dispositivo |
| EP1443900B1 (en) | 2001-11-13 | 2012-05-23 | Celator Pharmaceuticals, Inc. | Lipid carrier compositions with enhanced blood stability |
| US20030129224A1 (en) * | 2001-11-13 | 2003-07-10 | Paul Tardi | Lipid carrier compositions and methods for improved drug retention |
| US20030220284A1 (en) * | 2002-02-22 | 2003-11-27 | Patricia Yotnda | Delivery of adenoviral DNA in a liposomal formulation for treatment of disease |
| AU2003231157C1 (en) | 2002-04-29 | 2009-02-26 | Normoxys, Inc. | Inositol pyrophosphates, and methods of use thereof |
| AU2003237864B2 (en) | 2002-05-15 | 2008-12-18 | California Pacific Medical Center | Delivery of nucleic acid-like compounds |
| US7901708B2 (en) | 2002-06-28 | 2011-03-08 | Protiva Biotherapeutics, Inc. | Liposomal apparatus and manufacturing methods |
| US20040243101A1 (en) * | 2002-07-02 | 2004-12-02 | Gillis Edward M. | Minimally invasive drug delivery catheter |
| WO2004035032A2 (en) | 2002-08-20 | 2004-04-29 | Neopharm, Inc. | Pharmaceutical formulations of camptothecine derivatives |
| AR036316A1 (es) | 2002-08-29 | 2004-08-25 | Monte Verde S A | Una composicion farmaceutica de liposomas de tamano pequeno y metodo de preparacion |
| DE10242367A1 (de) | 2002-09-12 | 2004-03-18 | MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. | Thermolabiles Liposom mit geregelter Freigabetemperatur |
| US20040156888A1 (en) | 2002-11-26 | 2004-08-12 | Jensen Gerard M. | Liposomal formulations |
| EP1643972A4 (en) * | 2003-06-27 | 2010-01-20 | Smithkline Beecham Corp | STABILIZED LIPOSOMAL TOPOTECAN COMPOSITION AND METHOD |
| EP2338525A3 (en) * | 2003-07-09 | 2011-08-03 | California Pacific Medical Center | Remote detection of substance delivery to cells |
| WO2005087196A1 (ja) | 2004-03-17 | 2005-09-22 | Tokai University Educational System | 免疫応答システムを利用したドラッグデリバリーシステム |
| US8658203B2 (en) | 2004-05-03 | 2014-02-25 | Merrimack Pharmaceuticals, Inc. | Liposomes useful for drug delivery to the brain |
| RU2424792C2 (ru) | 2004-05-03 | 2011-07-27 | Хермес Байесайенсиз, Инк. | Липосомы, используемые для доставки лекарственных средств |
| AP2255A (en) | 2004-06-01 | 2011-07-21 | Yakult Honsha Kk | Irinotecan preparation. |
| CN101027065A (zh) | 2004-06-15 | 2007-08-29 | 陈献 | 磷脂组合物及其制备和使用方法 |
| CA2581714C (en) * | 2004-10-05 | 2017-09-12 | Avigen, Inc. | Stepped cannula |
| US20060129126A1 (en) * | 2004-11-19 | 2006-06-15 | Kaplitt Michael G | Infusion device and method for infusing material into the brain of a patient |
| US20060127467A1 (en) | 2004-12-14 | 2006-06-15 | Watkin Kenneth L | Nanoparticles for delivery of therapeutic agents using ultrasound and associated methods |
| EP2289535B8 (en) * | 2004-12-21 | 2018-08-08 | MUSC Foundation for Research Development | Compositions and methods for promoting wound healing and tissue regeneration |
| JP2006248978A (ja) | 2005-03-10 | 2006-09-21 | Mebiopharm Co Ltd | 新規なリポソーム製剤 |
| EP1951239A2 (en) | 2005-10-25 | 2008-08-06 | Celator Pharmaceuticals, Inc. | Fixed ratio drug combination treatments for solid tumors |
| WO2007076117A2 (en) | 2005-12-22 | 2007-07-05 | Celator Pharmaceuticals, Inc. | Liposomal formulations comprising secondary and tertiary amines and methods for preparing thereof |
| WO2007124465A2 (en) | 2006-04-20 | 2007-11-01 | Amgen Inc. | Stable emulsion formulations |
| GB0614835D0 (en) | 2006-07-26 | 2006-09-06 | Isis Innovation | Formation of bilayers of amphipathic molecules |
| HRP20131113T1 (hr) | 2007-02-16 | 2014-01-17 | Merrimack Pharmaceuticals, Inc. | Protutijela protiv erbb3 i njihova uporaba |
| ES2550759T3 (es) | 2007-08-17 | 2015-11-12 | Celator Pharmaceuticals, Inc. | Formulaciones farmacológicas de platino mejoradas |
| EP2197917A1 (en) | 2007-09-28 | 2010-06-23 | Universitätsspital Basel | Immunoliposomes for treatment of cancer |
| WO2009059449A1 (en) | 2007-11-05 | 2009-05-14 | Celsion Corporation | Novel thermosensitive liposomes containing therapeutic agents |
| US8067432B2 (en) | 2008-03-31 | 2011-11-29 | University Of Kentucky Research Foundation | Liposomal, ring-opened camptothecins with prolonged, site-specific delivery of active drug to solid tumors |
| US8852630B2 (en) | 2008-05-13 | 2014-10-07 | Yale University | Chimeric small molecules for the recruitment of antibodies to cancer cells |
| AU2013202947B2 (en) * | 2012-06-13 | 2016-06-02 | Ipsen Biopharm Ltd. | Methods for treating pancreatic cancer using combination therapies comprising liposomal irinotecan |
| WO2016168451A1 (en) | 2015-04-14 | 2016-10-20 | Merrimack Pharmaceuticals, Inc. | Compositions for improving the pharmacokinetics and therapeutic index of cancer treatment |
| HK1257216A1 (zh) | 2015-08-20 | 2019-10-18 | 益普生生物制药有限公司 | 使用脂质体伊立替康和parp抑制剂用於癌症治疗的组合疗法 |
| US20180110771A1 (en) | 2016-10-21 | 2018-04-26 | Ipsen Biopharm Ltd. | Liposomal Irinotecan Preparations |
| BR112018006922B1 (pt) * | 2015-10-16 | 2023-11-21 | Ipsen Biopharm Ltd | Composições de irinotecano lipossômico estabilizado para armazenamento |
| US20170202840A1 (en) | 2016-01-14 | 2017-07-20 | Merrimack Pharmaceuticals, Inc. | Treatment of pancreatic cancer with liposomal irinotecan |
| US20170333421A1 (en) | 2016-05-18 | 2017-11-23 | Ipsen Biopharm Ltd. | Population Pharmacokinetics of Liposomal Irinotecan |
| CN110402163A (zh) * | 2016-11-02 | 2019-11-01 | 易普森生物制药有限公司 | 使用包括脂质体伊立替康、奥沙利铂、5-氟尿嘧啶(和甲酰四氢叶酸)的组合疗法治疗胃癌 |
-
2005
- 2005-05-02 RU RU2006142766/15A patent/RU2424792C2/ru active
- 2005-05-02 ES ES23165619T patent/ES2967961T3/es not_active Expired - Lifetime
- 2005-05-02 CA CA2928387A patent/CA2928387A1/en not_active Abandoned
- 2005-05-02 AU AU2005240131A patent/AU2005240131C1/en active Active
- 2005-05-02 EP EP23165619.0A patent/EP4218730B1/en not_active Expired - Lifetime
- 2005-05-02 EP EP17150833.6A patent/EP3173073B1/en not_active Expired - Lifetime
- 2005-05-02 KR KR1020127017425A patent/KR101376895B1/ko not_active Expired - Lifetime
- 2005-05-02 KR KR1020067025074A patent/KR101223366B1/ko not_active Expired - Lifetime
- 2005-05-02 LT LTEP17150833.6T patent/LT3173073T/lt unknown
- 2005-05-02 CN CN200580022391.6A patent/CN1980637B/zh not_active Ceased
- 2005-05-02 KR KR1020137030020A patent/KR101462825B1/ko not_active Expired - Lifetime
- 2005-05-02 CA CA2821167A patent/CA2821167C/en not_active Expired - Lifetime
- 2005-05-02 PL PL05745505T patent/PL1746976T3/pl unknown
- 2005-05-02 CN CN201710790881.5A patent/CN107811971B/zh not_active Expired - Lifetime
- 2005-05-02 CN CN201410025888.4A patent/CN103948545B/zh not_active Expired - Lifetime
- 2005-05-02 US US11/121,294 patent/US8147867B2/en active Active
- 2005-05-02 PT PT57455057T patent/PT1746976T/pt unknown
- 2005-05-02 JP JP2007511506A patent/JP4971142B2/ja not_active Expired - Lifetime
- 2005-05-02 EP EP05745505.7A patent/EP1746976B1/en not_active Expired - Lifetime
- 2005-05-02 HU HUE17150833A patent/HUE068934T2/hu unknown
- 2005-05-02 DK DK05745505.7T patent/DK1746976T3/en active
- 2005-05-02 CA CA3006109A patent/CA3006109A1/en not_active Abandoned
- 2005-05-02 KR KR1020137004524A patent/KR101462819B1/ko not_active Expired - Lifetime
- 2005-05-02 FI FIEP17150833.6T patent/FI3173073T3/fi active
- 2005-05-02 ES ES05745505.7T patent/ES2616047T3/es not_active Expired - Lifetime
- 2005-05-02 RU RU2011112461D patent/RU2574926C9/ru active
- 2005-05-02 CA CA2566007A patent/CA2566007C/en not_active Expired - Lifetime
- 2005-05-02 UA UAA200612696A patent/UA86063C2/ru unknown
- 2005-05-02 WO PCT/US2005/015349 patent/WO2005107712A1/en not_active Ceased
- 2005-05-03 TW TW094114317A patent/TWI359029B/zh not_active IP Right Cessation
-
2006
- 2006-11-30 NO NO20065532A patent/NO345218B1/no active Protection Beyond IP Right Term
-
2011
- 2011-12-06 JP JP2011266612A patent/JP5502842B2/ja not_active Expired - Lifetime
-
2012
- 2012-03-09 US US13/416,204 patent/US8329213B2/en active Active
- 2012-10-17 US US13/654,373 patent/US8703181B2/en not_active Expired - Lifetime
-
2013
- 2013-11-22 JP JP2013241469A patent/JP5665950B2/ja not_active Expired - Lifetime
-
2014
- 2014-02-07 US US14/175,365 patent/US8992970B2/en not_active Expired - Lifetime
-
2015
- 2015-02-26 US US14/632,422 patent/US9717723B2/en not_active Expired - Lifetime
- 2015-10-09 US US14/879,302 patent/US9730891B2/en not_active Expired - Lifetime
- 2015-10-09 US US14/879,358 patent/US20160030342A1/en not_active Abandoned
- 2015-12-09 US US14/964,239 patent/US20160081928A1/en not_active Abandoned
- 2015-12-10 US US14/965,140 patent/US9724303B2/en not_active Expired - Lifetime
- 2015-12-11 US US14/966,458 patent/US9782349B2/en not_active Expired - Lifetime
- 2015-12-23 RU RU2015155368A patent/RU2757110C2/ru active
- 2015-12-28 US US14/979,666 patent/US20160106672A1/en not_active Abandoned
-
2016
- 2016-08-03 US US15/227,631 patent/US20160338956A1/en not_active Abandoned
- 2016-08-03 US US15/227,561 patent/US20160339014A1/en not_active Abandoned
- 2016-11-29 US US15/363,761 patent/US10413510B2/en not_active Expired - Lifetime
- 2016-11-29 US US15/363,978 patent/US10350201B2/en not_active Expired - Lifetime
- 2016-11-29 US US15/363,923 patent/US20170079912A1/en not_active Abandoned
- 2016-11-29 US US15/364,021 patent/US20170079914A1/en not_active Abandoned
-
2017
- 2017-07-07 LU LU00026C patent/LUC00026I2/de unknown
- 2017-07-10 FR FR17C1027C patent/FR17C1027I2/fr active Active
- 2017-07-10 NL NL300885C patent/NL300885I2/nl unknown
- 2017-07-31 US US15/664,976 patent/US11052079B2/en not_active Expired - Lifetime
-
2018
- 2018-02-14 US US15/896,389 patent/US10722508B2/en not_active Expired - Lifetime
- 2018-02-14 US US15/896,436 patent/US20180235954A1/en not_active Abandoned
-
2020
- 2020-06-19 US US16/906,601 patent/US20210137914A1/en not_active Abandoned
-
2021
- 2021-01-22 NO NO2021004C patent/NO2021004I1/no unknown
-
2022
- 2022-11-17 US US17/988,857 patent/US20230181567A1/en not_active Abandoned
-
2025
- 2025-01-17 FI FIC20250005C patent/FIC20250005I1/fi unknown
- 2025-01-21 HU HUS2500005C patent/HUS2500005I1/hu unknown
- 2025-01-23 LT LTPA2025504C patent/LTC3173073I2/lt unknown
- 2025-01-28 CY CY2025003C patent/CY2025003I1/el unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2012092119A5 (enExample) | ||
| CN108420793B (zh) | 一种空白混合胶束及其制备方法和应用 | |
| TWI359029B (en) | Liposomes useful for drug delivery | |
| AU2016309847B2 (en) | Liposomes with ginsenoside as membrane material and preparations and use thereof | |
| Ju et al. | Liposomes, modified with PTDHIV-1 peptide, containing epirubicin and celecoxib, to target vasculogenic mimicry channels in invasive breast cancer | |
| Stavnsbjerg et al. | Accelerated blood clearance and hypersensitivity by PEGylated liposomes containing TLR agonists | |
| JP6378170B2 (ja) | 異なる医薬品の制御送達のためのビヒクル | |
| Zhou et al. | The anticancer efficacy of paclitaxel liposomes modified with mitochondrial targeting conjugate in resistant lung cancer | |
| RU2721558C2 (ru) | Фармацевтическая композиция, содержащая анионное лекарственное средство, и способ ее получения | |
| JP6595463B2 (ja) | 気道に影響する増殖性疾患の処置に有用な製剤 | |
| Li et al. | On-demand combinational delivery of curcumin and doxorubicin via a pH-labile micellar nanocarrier | |
| ES2901102T3 (es) | Método para preparar una micela polimérica que contiene fármaco aniónico | |
| WO2010113984A1 (ja) | リポソーム組成物 | |
| EP2563337B1 (en) | Carrier and targeting system comprising a siosomal composition for intracellular delivery and targeting of active substance | |
| US12121573B2 (en) | Methods and agents including STING agonist to treat tumor | |
| TW201446251A (zh) | 治療癌症之細胞毒性劑 | |
| US20170027868A1 (en) | Peptide-conjugated liposome | |
| Bukchin et al. | Effect of growing glycosylation extents on the self-assembly and active targeting in vitro of branched poly (ethylene oxide)-poly (propylene oxide) block copolymers | |
| ES2329374T3 (es) | Formulaciones farmaceuticas que utilizan esfingolipidos de cadena corta y usos de las mismas. | |
| Yeo et al. | Drug carriers: not an innocent delivery man | |
| US10864280B2 (en) | Nanodroplet compositions for the efficient delivery of anti-cancer agents | |
| US20210338583A1 (en) | Cell membrane lipid-extracted nanoparticles (clens) for selective targeting, image analysis and cancer therapy | |
| WO2025184543A1 (en) | Compositions and methods for delivery of therapeutic compounds | |
| Jiang | Nanoscale Coordination Polymers Deliver Chemotherapeutics and Innate Immune Modulators for Cancer Therapy | |
| Bertoni et al. | Exploring the Use of Spray Congealing to Produce Solid Dispersions with Enhanced Indomethacin Bioavailability |